More Videos
- Is Merck A Drug Bellwether?
- Pfizer's Statin Study: What A Coincidence!
- Sam Waksal: "Moving On Up" To The East Side
- Another "Short" Story About Pfizer & Dendreon
- Predictions: 9 For '09 In Pharma
- Johnson & Johnson Is Latest FDA Casualty
- Genentech: Roche Says One Thing, Investors Say Another
- Schering-Plough: The Reviews Are In
- Pharma Updates And What You Need To Know
- The Emails Fly On GM, Ford CEO's Corporate Jets
- Yoshikami: Investing & the Obama Presidency
- Wall of Shame: Fortress Investment's Wes Edens
- Cramer to Geithner: Let FDIC Chair Keep Her Job
- Lightning Round: Boeing, Medtronic, Agrium and More
- Lightning Round OT: Continental, Amylin Pharma and More
- Sell Block: Cramer's Solution for Mortgage-Backed Paper Mess
- Toll Brothers CEO's Housing Outlook
- Making Money Off M&A
- Your First Move For Friday December 5th
- Charts Predict S&P Festive Rally Above 1,000
- BMW's Global Sales Plunge by a Quarter in Nov.
- Pros Say: Job Losses of 425,000; S&P to Fall to 700
- Bleak Jobs Data Forecasts Add to Automakers' Woes
- Euro Stocks Fall Ahead of US Jobs Data
- European Stocks to Open Sharply Lower
- Toshiba to Briefly Halt Chip Output on Weak Demand
- Boeing Mulls Pushing Back Dreamliner Deliveries
- Chief Executive Quits Australian Publisher Fairfax
Text Size 
 |
AP |
] and Cell Genesys [CEGE
Loading...
()
], much lower. After the closing bell Tuesday, Bristol-Myers Squibb [BMY
Loading...
()
] and Pfizer [PFE
Loading...
()
] announced a bloodclot drug they're working on didn't perform as well as they'd hoped it would in a clinical trial. As a result, they also said they won't be filing for Food and Drug Administration approval of the product next year, which had been their previous timeline.
Forty-five minutes later, AMLN and Eli Lilly [LLY
Loading...
()
] announced that four more Byetta patients died. Byetta is their twice-a-day injectable diabetes drug that lowers blood sugar and weight. That's on top of the two pancreatitis-related deaths the FDA disclosed last week. The companies say in this hyper-sensitive drug safety environment, they felt compelled to report the four other fatalities -- even though they don't think they had anything to do with the drug.
And then this morning, Cell Genesys announced it was stopping a late-stage study of its prostate cancer treatment because it saw more deaths in the group of patients getting the drug.
As one biotech executive so aptly put it at a recent investment conference, "It's a risky business." Given all the news within the last 12 hours or so, one could argue that's an understatement.
Questions? Comments?
Del.icio.us
Digg It
Data is a real-time snapshot *Data is delayed at least 15 minutes